Substance P Activates Responses Correlated with Tumour Growth in Human Glioma Cell Lines Bearing Tachykinin NK1 Receptors

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Jan 15

PMID 9888463

Citations 21

Authors

C Palma

F Nardelli

S Manzini

C A Maggi

Affiliations

Soon will be listed here.

Abstract

The neuropeptide substance P (SP), by stimulating tachykinin NK1 receptors (NK1R), triggers a number of biological responses in human glioma cells which are potentially relevant for tumour growth. First, radioligand binding studies demonstrated the presence of tachykinin NK1R on SNB-19, DBTRG-05 MG and U373 MG, but not on U138 MG and MOG-G-GCM human glioma cell lines. Second, application of SP or neurokinin A (NKA) to NK1R+ glioma cell lines increased the secretion of interleukin 6 (IL-6) and potentiated IL-6 secretion induced by IL-1beta. SP also up-regulated the release of transforming growth factor beta1 (TGF-beta1) by the U373 MG glioma cell line. Third, SP induced new DNA synthesis and enhanced the proliferation rate of NK1R+, but not of NK1R- glioma cell lines. Also, NKA stimulated the proliferation and cytokine secretion in NK1R+ glioma cell lines. All the stimulant effects of SP/NKA on NK1R+ glioma cell lines were completely blocked by a specific tachykinin NK1R antagonist, MEN 11467. These data support the potential use of tachykinin NK1R antagonist for controlling the proliferative rate of human gliomas.

Citing Articles

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.

Targeting the peripheral neural-tumour microenvironment for cancer therapy.

Yaniv D, Mattson B, Talbot S, Gleber-Netto F, Amit M Nat Rev Drug Discov. 2024; 23(10):780-796.

PMID: 39242781 DOI: 10.1038/s41573-024-01017-z.

Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families.

Sanchez M, Rodriguez F, Covenas R Cancers (Basel). 2023; 15(6).

PMID: 36980580 PMC: 10046800. DOI: 10.3390/cancers15061694.

The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.

Munoz M, Arguelles S, Rosso M, Medina R, Covenas R, Ayala A Biomed Res Int. 2022; 2022:6291504.

PMID: 35434136 PMC: 9006081. DOI: 10.1155/2022/6291504.

In Vitro Biological Evaluation of Aprepitant Based Lu-Radioconjugates.

Halik P, Kozminski P, Matalinska J, Lipinski P, Misicka A, Gniazdowska E Pharmaceutics. 2022; 14(3).

PMID: 35335981 PMC: 8949964. DOI: 10.3390/pharmaceutics14030607.

References

Frei K, Piani D, Malipiero U, van Meir E, Tribolet N, Fontana A . Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo. J Immunol. 1992; 148(10):3140-6. View

Eistetter H, Mills A, Brewster R, Alouani S, Rambosson C, Kawashima E . Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells. Glia. 1992; 6(2):89-95. DOI: 10.1002/glia.440060203. View

Lee C, Tung W, Young J . Tachykinin-stimulated inositol phospholipid hydrolysis and taurine release from human astrocytoma cells. J Neurochem. 1992; 59(2):406-14. DOI: 10.1111/j.1471-4159.1992.tb09386.x. View

Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi C . Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990; 40(2):264-78. DOI: 10.1016/0026-2862(90)90024-l. View

Ausiello C, Palma C, Maleci A, Spagnoli G, Amici C, Antonelli G . Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. Eur J Cancer. 1991; 27(5):646-50. DOI: 10.1016/0277-5379(91)90235-6. View

Jennings M, Maciunas R, Carver R, Bascom C, Juneau P, Misulis K . TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer. 1991; 49(1):129-39. DOI: 10.1002/ijc.2910490124. View

Weller M, Stevens A, Sommer N, Melms A, Dichgans J, Wietholter H . Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. J Neurol Sci. 1991; 104(2):215-21. DOI: 10.1016/0022-510x(91)90313-v. View

Roszman T, Elliott L, Brooks W . Modulation of T-cell function by gliomas. Immunol Today. 1991; 12(10):370-4. DOI: 10.1016/0167-5699(91)90068-5. View

Schindler R, Mancilla J, Endres S, Ghorbani R, Clark S, Dinarello C . Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990; 75(1):40-7. View

10.

Allen J, Hoyle N, Yeats J, Ghatei M, Thomas D, Bloom S . Neuropeptides in neurological tumours. J Neurooncol. 1985; 3(3):197-202. DOI: 10.1007/BF00165179. View

11.

Michel J, Sakamoto N, Bouvier R, Tommasi M, Pearson J . Substance P-immunoreactive astrocytes related to deep white matter and striatal blood vessels in human brain. Brain Res. 1986; 377(2):383-7. DOI: 10.1016/0006-8993(86)90886-3. View

12.

Mantyh P, Johnson D, Boehmer C, Catton M, Vinters H, Maggio J . Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci U S A. 1989; 86(13):5193-7. PMC: 297584. DOI: 10.1073/pnas.86.13.5193. View

13.

Kostyk S, Kowall N, Hauser S . Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res. 1989; 504(2):284-8. DOI: 10.1016/0006-8993(89)91369-3. View

14.

Bodmer S, Strommer K, Frei K, Siepl C, Tribolet N, Heid I . Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989; 143(10):3222-9. View

15.

Munson P, Rodbard D . Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107(1):220-39. DOI: 10.1016/0003-2697(80)90515-1. View

16.

Delean A, Munson P, Rodbard D . Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978; 235(2):E97-102. DOI: 10.1152/ajpendo.1978.235.2.E97. View

17.

Gitter B, Regoli D, Howbert J, Glasebrook A, Waters D . Interleukin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol. 1994; 51(1):101-8. DOI: 10.1016/0165-5728(94)90134-1. View

18.

Goso C, Potier E, Manzini S, Szallasi A . Comparison of tachykinin NK1 receptors in human IM9 and U373 MG cells, using antagonist (FK888, (+/-)-CP-96,345, and RP 67580) binding. Eur J Pharmacol. 1994; 254(3):221-7. DOI: 10.1016/0014-2999(94)90458-8. View

19.

Palma C, Goso C, Manzini S . Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett. 1994; 171(1-2):221-4. DOI: 10.1016/0304-3940(94)90644-0. View

20.

Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A . Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 1995; 55(13):2936-44. View